Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 9.8% – Still a Buy?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) traded up 9.8% during mid-day trading on Tuesday . The company traded as high as $31.26 and last traded at $30.88. 235,068 shares were traded during trading, a decline of 84% from the average session volume of 1,484,420 shares. The stock had previously closed at $28.13.

Analyst Ratings Changes

A number of equities analysts recently commented on DYN shares. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday. Stifel Nicolaus lifted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Chardan Capital reissued a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday. Morgan Stanley upped their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Stock Up 16.4 %

The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of -9.59 and a beta of 1.10. The company has a 50-day moving average price of $32.64 and a 200-day moving average price of $35.12.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities analysts expect that Dyne Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Dirk Kersten sold 23,671 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total value of $836,769.85. Following the completion of the transaction, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO John Cox acquired 32,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. This represents a -100.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dirk Kersten sold 23,671 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total value of $836,769.85. Following the completion of the transaction, the director now directly owns 99,652 shares in the company, valued at $3,522,698.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 158,975 shares of company stock valued at $5,693,789 in the last quarter. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently modified their holdings of DYN. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Dyne Therapeutics by 24.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,617 shares of the company’s stock worth $812,000 after buying an additional 5,696 shares during the period. Oppenheimer & Co. Inc. bought a new stake in shares of Dyne Therapeutics in the 1st quarter valued at about $810,000. Swiss National Bank boosted its stake in Dyne Therapeutics by 41.5% during the 1st quarter. Swiss National Bank now owns 85,200 shares of the company’s stock worth $2,419,000 after acquiring an additional 25,000 shares during the last quarter. Sei Investments Co. bought a new position in Dyne Therapeutics during the 1st quarter worth approximately $693,000. Finally, Russell Investments Group Ltd. increased its stake in Dyne Therapeutics by 1.4% in the first quarter. Russell Investments Group Ltd. now owns 101,943 shares of the company’s stock valued at $2,894,000 after purchasing an additional 1,447 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.